SORRENTO THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 15th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
This Amended and Restated Employment Agreement (this “Agreement”), dated as of May 9, 2017 (the “Effective Date”), is made by and between Sorrento Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Henry Ji, Ph.D. (the “Executive”) (collectively referred to herein as the “Parties”).
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 15th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 23, 2017 (the “Fourth Amendment Effective Date”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), Concortis Biosystems, Corp., a Delaware corporation, Ark Animal Health, Inc., a Delaware corporation, TNK Therapeutics, Inc., a Delaware corporation, Sorrento Biologics, Inc., a Delaware corporation, Scintilla Pharmaceuticals, Inc., a Delaware corporation, LA Cell, Inc., a Delaware corporation, SiniWest Holding Corp., a Delaware corporation, Levena Biopharma US, Inc., a Delaware corporation, BioServ Corporation (formerly known as Sorrento BioServices, Inc.), a Delaware corporation, Scilex Pharmaceuticals Inc., a Delaware corporation, SNAN Holdco LLC, a Delaware limited liability company and each of their Qualified Subsidiaries (together with “Parent” hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions
AMENDMENT NO. 3 TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 15th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
This Amendment No. 3 to Stock Purchase Agreement (this “Amendment”) is dated as of March 14, 2017 by and between TNK Therapeutics, Inc., a Delaware corporation (the “Purchaser”), and Richard P. Junghans, M.D., Ph.D., as the Stockholders’ Representative (the “Representative”).
